
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc. has garnered mixed reviews as it approaches its reporting date. One expert expresses confidence in the new CEO and anticipates a potential rebound in beer and cocktail sales, suggesting a positive outlook for the company's future. Conversely, another expert highlights current challenges faced by the alcohol sector, including declining popularity and negative impacts attributed to external factors like ICE raids. This expert notes a significant -36% drop in the stock's value this year and mentions that the stock is trading at a low 12x price-to-earnings ratio. However, this low PE is deemed warranted due to weakening sales trends and increasing competition from GLP-1 drugs. Overall, the outlook suggests uncertainty driven by external pressures and internal adjustments within the company.
Their focus is their internal liquor brands, whose sales have been flat. They invested in cannabis (Canopy) as a way to grow, but is stalled. We'll see about the long-term. Invest elsewhere in consumer staples.
The push out of a senior executive, Bruce Linton, at WEED-T is a good signal for the company he thinks. There was not damage done by the Exec and he has done well personally by the agreement and is off the Board as well. This gives the Exec a great opportunity to sell his shares at a great value. The company has a $40 billion market cap. Constellation Brands had to take a charge against their $5 billion investment. Right now, Norman believes this is not an investable space yet -- the real leaders have not yet emerged. He expects further shake-outs in the space to come. There is no real brand recognition today.
One of the world’s largest beverage makers. Is a high risk stock. Probably has about as good a chart you can have. Just seems to be in a sidewise consolidation pattern right now. With respect to their Canopy investment, the marijuana space has dropped significantly and this will impact the share price of Constellation.
It is interesting that they are investing into Canopy. He thinks it is more like a hedge for them. In the context it is a cheap hedge. This shouldn’t be the basis to invest in the stock. The marijuana space is nascent. He wouldn’t analyze the company with that component. He wouldn’t invest in this stock.
He owned this before they bought in Canopy. They own Corona and other Mexican brands, plus wine. The beers have been growing very well. STZ has one of the best growth rates in a sluggish sector. He isn't a cannabis bull, but he sees upside in this space. (1.4% dividend, Analysts' price target: $242.00)